Skip to main content

Table 3 Cox proportional hazards regression models for mortality and associated risk factors

From: A comparative analysis on characteristics and mortalities of four key transmission populations on antiretroviral therapy: a retrospective cohort study in Northwest China

 

All-cause deaths

AIDS-related deaths

Non-AIDS-related deaths

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

Gender

 Male

1.00

–

–

–

1.00

–

 Female

1.93 (1.10–3.37)

–

–

–

3.83 (1.83–7.98)

–

Age at ART initiation

 18–29

1.00

1.00

1.00

–

1.00

1.00

 30–39

2.89 (1.38–6.08)

2.02 (0.95–4.30)

2.89 (1.19–7.03)

–

1.88 (0.31–11.23)

1.43 (0.24–8.61)

 ≥ 40

9.20 (4.78–17.72)

5.62 (2.85–11.10)

7.13 (3.22–15.78)

–

20.55 (4.96–85.22)

14.10 (3.37–59.12)

Marital status

 Unmarried

1.00

–

1.00

–

1.00

–

 Married

3.48 (2.20–5.51)

–

2.63 (1.49–4.62)

–

8.96 (3.14–25.56)

–

 Divorced

3.04 (1.69–5.48)

–

2.74 (1.34–5.60)

–

6.67 (1.95–22.80)

–

 Widowed

10.46 (4.29–25.52)

–

4.89 (1.13–21.07)

–

43.28 (10.81–173.30)

–

Transmission category

 Homosexuals

1.00

1.00

1.00

–

1.00

1.00

 Heterosexuals

2.15 (1.40–3.31)

1.49 (0.97–2.31)

1.89 (1.06–3.37)

–

2.75 (1.36–5.59)

2.07 (1.01–4.20)

 IDUs

3.01 (0.94–9.64)

1.25 (0.39–4.06)

5.07 (1.55–16.59)

–

–

–

 Blood and plasma donors

9.94 (3.01–31.92)

5.21 (1.54–17.67)

–

–

29.67 (8.61–102.29)

19.81 (5.62–69.89)

BMI (kg/ m2)

 < 18.5

1.00

1.00

1.00

–

–

–

 18.5–24.9

0.40 (0.27–0.60)

0.62 (0.40–0.96)

0.46 (0.27–0.79)

–

–

–

 25–19.9

0.20 (0.08–0.46)

0.39 (0.16–0.97)

0.12 (0.03–0.51)

–

–

–

 ≥ 30

0.66 (0.16–2.76)

1.56 (0.36–6.76)

0.60 (0.08–4.49)

–

–

–

CD4 + lymphocyte counts (/μl)

 < 50

1.00

1.00

1.00

1.00

1.00

–

 50–99

0.71 (0.42–1.21)

0.87 (0.51–1.50)

0.63 (0.33–1.22)

0.78 (0.40–1.52)

0.92 (0.34–2.49)

–

 100–199

0.50 (0.31–0.81)

0.94 (0.56–1.57)

0.38 (0.20–0.71)

0.67 (0.350–1.30)

0.95 (0.42–2.15)

–

 200–349

0.13 (0.08–0.23)

0.32 (0.17–0.59)

0.10 (0.05–0.20)

0.21 (0.09–0.46)

0.21 (0.08–0.53)

–

 350–499

0.04 (0.02–0.12)

0.15 (0.05–0.44)

–

–

0.18 (0.06–0.57)

–

 ≥ 500

0.06 (0.02–0.17)

0.25 (0.09–0.75)

–

–

0.19 (0.05–0.70)

–

Types of comorbidities

 0

1.00

1.00

1.00

1.00

1.00

1.00

 1

6.10 (3.95–9.43)

2.66 (1.64–4.30)

9.25 (5.26–16.24)

3.92 (2.14–7.17)

3.99 (1.91–8.34)

2.70 (1.27–5.74)

 2

10.53 (6.26–17.69)

3.61 (2.03–6.40)

13.74 (6.92–27.31)

4.61 (2.20–9.65)

7.58 (3.19–17.99)

5.27 (2.19–12.66)

 ≥ 3

13.41 (7.34–24.51)

3.67 (1.86–7.26)

14.70 (6.26–34.480)

4.46 (1.81–10.98)

9.91 (3.69–26.66)

6.75 (2.42–18.87)

  1. IDU injecting drug user, ART antiretroviral therapy, BMI body mass index. Boldface indicates statistical significance